Is Akums Drugs & Pharmaceuticals Ltd. stock a buy or sell right now?

Based on current indicators, Akums Drugs & Pharmaceuticals Ltd. shows a Buy signal, supported by strong momentum and a confirmed uptrend.

What is Akums Drugs & Pharmaceuticals Ltd.’s RSI?

RSI is 65.01, showing balanced momentum within the normal range.

What does MACD indicate for AKUMS.NS?

MACD at 15.53 signals bullish momentum with buyers in control.

What are Akums Drugs & Pharmaceuticals Ltd.’s key support and resistance levels?

Support sits around $485.14, while resistance is near $567.92.

Akums Drugs & Pharmaceuticals Ltd.

AKUMS.NS•NSE

Healthcare

Drug Manufacturers - Specialty & Generic

₹552.80

₹5.50(1.005%)

Indian Market opens in 11h 0m

Akums Drugs & Pharmaceuticals Ltd. (AKUMS.NS) Stock Technical Analysis & Trading Signals

Live technical indicators, trading signals, and momentum insights for Akums Drugs & Pharmaceuticals Ltd. (NSE:AKUMS.NS).

Disclaimer for Technical Analysis Page

The technical indicators and trading signals shown on this page are for informational purposes only and do not constitute financial advice. Stock market investments involve risk, and past performance is not a guarantee of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.Read our Full Disclaimer

AKUMS.NS Technical Analysis Summary

Akums Drugs & Pharmaceuticals Ltd. stock currently shows a bullish trend, supported by momentum and strong buying pressure.

Overall Sentiment:Buy

Momentum:Bullish (RSI: 65.01)

Trend Strength:Strong (ADX: 32.93)

Volatility:Medium (ATR: 19.30)

Support/Resistance:$485.14 – $567.92 (Bollinger Bands)

This mix signals that Akums Drugs & Pharmaceuticals Ltd. is trading in a balanced range with no clear breakout yet.

Momentum Indicators

RSI (14): 65.01

Bullish

Above midpoint suggests upward bias.

Stochastic %K: 83.52

Bearish

Overbought levels may trigger pullback.

Williams %R: -7.44

Bearish

Overbought levels may trigger correction.

Rate of Change (ROC): 8.47

Strongly Bullish

Strong upside momentum.

Takeaway:Akums Drugs & Pharmaceuticals Ltd. shows strong bullish momentum, with buyers firmly in control.

Trend & Volatility

MACD: 15.53

Bullish

Bullish, trend momentum is strengthening.

ADX: 32.93

Strong

Strong trend, momentum well established.

ATR (14): 19.30

Rising

Rising volatility, market activity increasing.

CCI (14): 155.22

Bearish Risk

Bearish risk, overbought levels suggest caution.

Takeaway:Akums Drugs & Pharmaceuticals Ltd. shows overheated trend conditions, with risk of sharp pullback.

Support & Resistance indicators

Bollinger Bands

Upper Band

$567.92

Middle Band (SMA 20)

$526.53

Lower Band

$485.14

Current Position

Within Bands

Takeaway:Akums Drugs & Pharmaceuticals Ltd. trades closer to resistance, supported by stronger momentum within bands.

Keltner Channels

Upper Channel

$565.75

Middle Line (EMA 20)

$527.16

Lower Channel

$488.57

Squeeze Status

No Squeeze

Takeaway:Akums Drugs & Pharmaceuticals Ltd. trades above the trend line, showing healthy momentum within the channel.

Volume & Money Flow Analysis

On-Balance Volume5.56M

Money Flow Index84.09Bearish risk, overbought conditions may trigger pullback.

Relative Vigor Index69.64Bullish, price momentum strongly favors buyers.

Overall Takeaway:AKUMS.NS shows overheated money flow, with risk of pullback from overbought conditions.

Technical Trading Signals Summary

Based on the current technical analysis of Akums Drugs & Pharmaceuticals Ltd., here are the key trading signals and recommendations:

Bullish Signals

RSI above 50 → positive momentum from buyers.

MACD above 0 → bullish trend confirmation.

ADX above 20 → strong underlying trend.

Price trading above middle Bollinger Band → mid-term support intact.

Bearish Signals

MFI above 80 → overbought conditions may limit upside.

Overall Recommendation:Akums Drugs & Pharmaceuticals Ltd. currently shows a Buy with caution signal — momentum and trend strength are positive, but price is close to resistance and may face short-term pullbacks.